(12) United States Patent (10) Patent No.: US 7,888,381 B2 Duan Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US007888381 B2 (12) United States Patent (10) Patent No.: US 7,888,381 B2 Duan et al. (45) Date of Patent: Feb. 15, 2011 (54) MODULATORS OF GLUCOCORTICOID Salem, M.A.I. et al., “Some Reactions with Cinnamoyl RECEPTOR, AP-1, AND/OR NF-kBACTIVITY, Cyclohexenone Derivatives'. Egypt. J. Chem... vol. 30, No. 1, pp. AND USE THEREOF 89-95 (1987). Nagakura, et al., Journal of Medicinal Chemistry, vol. 22, No. 1, pp. (75) Inventors: Jingwu Duan, Yardley, PA (US); 48-52, (1979). Zhonghui Lu, King of Prussia, PA (US); Chaloner, et al., Tetrahedron, vol. 48, No. 37, pp. 8101-8116 (1992). Chemical Abstracts, Heterocycles, 36(12), 2839-50, (1993). David S. Weinstein, East Windsor, NJ Chemical Abstracts, Heterocycles, 37(2), 967-78 (1994). (US); Bin Jiang, Norristown, PA (US) Chemical Abstracts, Chemie, 36B(9), 1147-8 (1981). (73) Assignee: Bristol-Myers Squibb Company, Chemical Abstracts, Indian Journal of Chemistry, 15(8), 690-3 (1977). Princeton, NJ (US) Chemical Abstracts, Indian Journal of Chemistry, 15B(4), 359-63 (1977). (*) Notice: Subject to any disclaimer, the term of this Chemical Abstracts, Zh. Org. Khim.; vol. 1, 2232-2236 (1965). patent is extended or adjusted under 35 Chemical Abstracts, Farmaco, vol. 47, No. 3, 357-365 (1992). U.S.C. 154(b) by 632 days. Chemical Abstracts, Justus Liebigs Ann., vol. 287, p. 149, (1895). Chemical Abstracts, Tetrahedron, vol. 26, 5793-5801 (1970). (21) Appl. No.: 11/451,660 Chemical Abstracts, Eur, Journal of Organic Chemistry, vol. 9, 1673 1680 (2001). (22) Filed: Jun. 13, 2006 Chemical Abstracts, Tetrahedron Lett., vol. 34, No. 31, 4957-4960 (1993). (65) Prior Publication Data Chemical Abstracts, Journal of the Chemical Society, vol. 10, 2749 2750 (1990). US 2007/O1294OO A1 Jun. 7, 2007 Chemical Abstracts, Recl. Tray. Chim. Pays-Bas, vol. 77, 792-798, (1958). Related U.S. Application Data Chemical Abstracts, Can. J. Chem... vol. 50, 726-736, (1972). (60) Provisional application No. 60/690,355, filed on Jun. CAS Registry No. 344573-23-5 (no references). 14, 2005, provisional application No. 60/782,636, CAS Registry No. 116373-85-4 (no references). filed on Mar. 15, 2006. Baldwin, Jr., A.S., “The transcription factor NF-kB and human dis ease'. The Journal of Clinical Investigation, vol. 107. No. 1. pp. 3-6 (51) Int. Cl. (2001). CO7D 23L/56 (2006.01) (Continued) AOIN 43/56 (2006.01) (52) U.S. Cl. .................................... 514/406; 548/360.1 Primary Examiner Joseph McKane (58) Field of Classification Search ....................... None Assistant Examiner—Sun Jae Y Loewe See application file for complete search history. (74) Attorney, Agent, or Firm Burton Rodney; Laurelee A. Duncan (56) References Cited (57) ABSTRACT U.S. PATENT DOCUMENTS 3,452,085 A 6, 1969 Francesco et al. Non-steroidal compounds are provided which are useful in 3,736,332 A 5, 1973 Butula 4,166,131 A 8/1979 Payne treating diseases associated with modulation of the glucocor 6,083,969 A 7/2000 Ferro et al. ticoid receptor, AP-1, and/or NF-kB activity including obe 2005/0090529 A1 4/2005 McAlpine et al. sity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) FOREIGN PATENT DOCUMENTS DE 235461.0 A1 5, 1974 EP 0474991 A1 3, 1992 (I) JP 54141768 11, 1979 JP 55 019226 2, 1980 WO WOO1/02369 1, 2001 WO WO O2, 10137 2, 2002 WO WOO3,035.625 5, 2003 (R1)04 WO WOO3,061651 T 2003 WO WOO3,O86294 10, 2003 WO WO 2004/009017 1, 2004 or an enantiomer, a diastereomer, a pharmaceutically accept WO WO 2004/O10995 2, 2004 WO WO 2004/075840 9, 2004 able salt, or hydrate thereof, where J is selected from NR or WO WO 2004/094388 11, 2004 C(R)(R); K is selected from NR or C(R)(Rs); L is WO WO 2005/095.353 10/2005 selected from NR or C(R)(R); and A, X,Y. R. R. R. R. R. Rs. Rs. R. R. Rs. Rio R, and n are defined herein. OTHER PUBLICATIONS Also provided are pharmaceutical compositions and methods Auwers et al., caplusan 1924:6075.* of treating obesity, diabetes and inflammatory or immune Hamed, A.A. et al., “Reactivity of 4,6-Diacetylcyclohexenones associated diseases comprising said compounds. Towards Some Nucleophilic Reagents”, Egypt. J. Chem... vol. 29, No. 4, pp. 485-493 (1986). 6 Claims, No Drawings US 7,888,381 B2 Page 2 OTHER PUBLICATIONS Jonat, C. et al., “Antitumor Promotion and Antiinflammation: Down Modulation of AP-1 (Fos/Jun) Activity by Glucocorticoid Hor Bekhit, A.A. et al., “Non-Steroidal anti-inflammatory agents: Syn mone”. Cell, vol. 62, pp. 1189-1204 (1990). thesis of novel benzopyrazolyl, benzoxazolyl and quinazolinyl Kamei, Y. et al., "A CBP Integrator Complex Mediates. Transcrip derivatives of 4(3 H)-quinazolinones'. Pharmazie, vol.53, No. 8, pp. tional Activation and AP-1 Inhibition by Nuclear Receptors”. Cell, 539-543 (1998). vol. 85, pp. 403-414 (1996). Bouillon, J.-P. et al., “Spiroannelation Starting from Manning, A.M. et al., “Targeting JNK for Therapeutic Benefit: From B-Trifluoroacetylpyrrollidone'. Polish J. Chem... vol. 68, pp. 2315 Junk to Gold”. Nature Reviews Drug Discovery, vol. 2, pp. 554-565 2322 (1994). (2003). Burke, J.R., “Targeting IKB kinase for the treatment of inflammatory Miesfeld, R. et al., “Characterization of a steroid hormone receptor and other disorders”. Current Opinion in Drug Discovery & Devel gene and mRNA in wild-type and mutant cells', Nature, vol.312, pp. opment, vol. 6, No. 5, pp. 720-728 (2003). 779-781 (1984). Caldenhoven, E. et al., “Negative Cross-Talk between RelA and the Peltz, G., “Transcription factors in immune-mediated disease'. Cur Glucocorticoid Receptor: A Possible Mechanism for the Antiinflam rent Opinion in Biotechnology, vol. 8, pp. 467-473 (1997). matory Action of Glucocorticoids'. Molecular Endocrinology, vol.9, Reichardt, H.M. et al., “DNA Binding of the Glucocorticoid Receptor No. 4, pp. 401-412 (1995). Is Not Essential for Survival”. Cell, vol. 93, pp. 531-541 (1998). Chakravarti. D. et al., “Role of CBP/P300 in nuclear receptor signal Reichardt, H.M. et al., “Repression of inflammatory responses in the ling”. Nature, vol. 383, pp. 99-103 (1996). absence of DNA binding by the glucocorticoid receptor'.The EMBO Diamond, M.I. et al., “Transcription Factor Interactions: Selectors of Journal, vol. 20, No. 24, pp. 7168-7173 (2001). Positive or Negative Regulation from a Single DNA Element”. Sci Weinberger, C. et al., “Domain structure of human glucocorticoid ence, vol. 249, pp. 1266-1272 (1990). receptor and its relationship to the v-erb-A oncogene product”. Elkasaby, M.A., “Some Reactions of 6-Acetyl-5-aryl-4- Nature, vol. 318, pp. 670-672 (1985). carbethoxy-3-methylcyclohex-2-enones”, Indian Journal of Chemis Weinberger, C. et al., “Identification of Human Glucocorticoid try, vol. 15B, pp. 690-693 (1977). Receptor Complementary DNA Clones by Epitope Selection”, Sci Firestein, G.S. et al., “Signal Transduction and Transcription Factors ence, vol. 228, pp. 740-742 (1985). in Rheumatic Disease'. Arthritis & Rheumatism, vol. 42, No. 4, pp. Yang-Yen, H.-F. et al., “Transcriptional Interference between c-Jun 609-621 (1999). and the Glucocorticoid Receptor: Mutual Inhibition of DNA Binding Hamed, A.A. et al., “Reactivity of 4,6-Diacetylcyclohexenones Due to Direct Protein-Protein Interaction”. Cell, vol. 62, pp. 1205 Towards Some Nucleophilic Reagents'. Polish Journal of Chemistry, 1215 (1990). vol. 59, pp. 1161-1166 (1985). * cited by examiner US 7,888,381 B2 1. 2 MODULATORS OF GLUCOCORTICOD Glucocorticoids which interact with GR have been used for RECEPTOR, AP-1, AND/OR NF-kBACTIVITY, over 50 years to treat inflammatory diseases. It has been AND USE THEREOF clearly shown that glucocorticoids exert their anti-inflamma tory activity via the inhibition by GR of the transcription This application claims priority from U.S. Provisional factors NF-kB and AP-1. This inhibition is termed transre Application Ser. Nos. 60/690,355 and 60/782,636 filed Jun. pression. It has been shown that the primary mechanism for 14, 2005 and Mar. 15, 2006, respectively. inhibition of these transcription factors by GR is via a direct physical interaction. This interaction alters the transcription FIELD OF THE INVENTION factor complex and inhibits the ability of NF-kB and AP-1 to 10 stimulate transcription. See Jonat, C., et al., Cell, 62, 1189 The present invention relates to new non-steroidal com (1990); Yang-Yen, H. F., et al., Cell, 62, 1205 (1990); Dia pounds which are effective modulators of the glucocorticoid mond, M.I., et al., Science 249, 1266 (1990); and Calden receptor, AP-1, and/or NF-kB activity and thus are useful in hoven, E. et al., Mol. Endocrinol., 9, 401 (1995). Other treating diseases Such as obesity, diabetes and inflammatory mechanisms such as sequestration of co-activators by GR or immune associated diseases, and to a method for using 15 have also been proposed. See Kamer Y., et al., Cell, 85, 403 Such compounds to treat these and related diseases. (1996); and Chakravarti, D., et al., Nature, 383, 99 (1996). In addition to causing transrepression, the interaction of a BACKGROUND OF THE INVENTION glucocorticoid with GR can cause GR to induce transcription of certain genes. This induction of transcription is termed The transcription factors NF-kB and AP-1 are involved in transactivation. Transactivation requires dimerization of GR regulating the expression of a number of genes involved in and binding to a glucocorticoid response element (GRE). mediating inflammatory and immune responses. NF-KB Recent studies using a transgenic GR dimerization defec regulates the transcription of genes including TNF-C., IL-1, tive mouse which cannot bind DNA have shown that the IL-2, IL-6, adhesion molecules (such as E-selectin) and transactivation (DNA binding) activities of GR could be sepa chemokines (such as Rantes), among others.